Overview

Surgery Plus Target-reduction Chemoradiotherapy vs Regular Chemoradiotherapy for Primary Locally Resectable Nasopharyngeal Carcinoma

Status:
Recruiting

Trial end date:
2028-03-31

Target enrollment:

Participant gender:

Summary

Through a prospective clinical trial, we intend to combine endoscopic nasopharyngectomy, induction chemotherapy, target-reduction intensity-modulated radiotherapy and concurrent chemotherapy as an experimental treatment for patients with newly diagnosed resectable nasopharyngeal carcinoma to illuminate whether combined endoscopic nasopharyngectomy could bring patients better local control and lower adverse reactions.

Phase:

N/A

Details

Lead Sponsor:

Sun Yat-sen University

Treatments:

Gemcitabine